These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35687107)

  • 21. Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions.
    Anker SD; Siddiqi TJ; Filippatos G; Zannad F; Ferreira JP; Pocock SJ; Brueckmann M; Zeller C; Packer M; Butler J
    Eur J Heart Fail; 2022 Aug; 24(8):1400-1405. PubMed ID: 35604680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M; Anker SD; Butler J; Filippatos G; Pocock SJ; Carson P; Januzzi J; Verma S; Tsutsui H; Brueckmann M; Jamal W; Kimura K; Schnee J; Zeller C; Cotton D; Bocchi E; Böhm M; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Janssens S; Zhang J; Gonzalez Juanatey JR; Kaul S; Brunner-La Rocca HP; Merkely B; Nicholls SJ; Perrone S; Pina I; Ponikowski P; Sattar N; Senni M; Seronde MF; Spinar J; Squire I; Taddei S; Wanner C; Zannad F;
    N Engl J Med; 2020 Oct; 383(15):1413-1424. PubMed ID: 32865377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD; Butler J; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure-Valenzuela E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Carson P; Lam CSP; Marx N; Zeller C; Sattar N; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    N Engl J Med; 2021 Oct; 385(16):1451-1461. PubMed ID: 34449189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
    Butler J; Packer M; Filippatos G; Ferreira JP; Zeller C; Schnee J; Brueckmann M; Pocock SJ; Zannad F; Anker SD
    Eur Heart J; 2022 Feb; 43(5):416-426. PubMed ID: 34878502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
    Neuen BL; Oshima M; Perkovic V; Agarwal R; Arnott C; Bakris G; Cannon CP; Charytan DM; Edwards R; Górriz JL; Jardine MJ; Levin A; Neal B; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Mahaffey KW; Heerspink HJL
    Eur Heart J; 2021 Dec; 42(48):4891-4901. PubMed ID: 34423370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
    Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
    J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Sattar N; Brueckmann M; Jamal W; Cotton D; Iwata T; Zannad F;
    J Am Coll Cardiol; 2021 Mar; 77(11):1381-1392. PubMed ID: 33736819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
    Khan MS; Butler J; Anker SD; Filippatos G; Ferreira JP; Pocock SJ; Januzzi JL; Piña IL; Böhm M; Ponikowski P; Verma S; Brueckmann M; Vedin O; Zeller C; Zannad F; Packer M
    J Am Heart Assoc; 2023 Jan; 12(1):e027652. PubMed ID: 36565199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced.
    Filippatos G; Anker SD; Butler J; Farmakis D; Ferreira JP; Gollop ND; Brueckmann M; Iwata T; Pocock S; Zannad F; Packer M;
    Eur J Heart Fail; 2022 Dec; 24(12):2297-2304. PubMed ID: 36194680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapies for the treatment of heart failure with preserved ejection fraction.
    Meier ML; Pierce KN
    Am J Health Syst Pharm; 2022 Aug; 79(17):1424-1430. PubMed ID: 35524990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M; Anker S; Mahfoud F; Lauder L; Filippatos G; Ferreira JP; Pocock SJ; Brueckmann M; Saloustros I; Schler E; Wanner C; Zannad F; Packer M; Butler J
    Eur Heart J; 2023 Feb; 44(5):396-407. PubMed ID: 36478225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing potassium levels in critically ill patients with heart failure: application of a group-based trajectory model.
    Lin Z; Zheng J; Liu X; Hu X; Fuxian R; Gao D
    ESC Heart Fail; 2023 Feb; 10(1):57-65. PubMed ID: 36151847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
    Packer M; Butler J; Filippatos G; Zannad F; Ferreira JP; Zeller C; Brueckmann M; Jamal W; Pocock SJ; Anker SD;
    Eur J Heart Fail; 2020 Dec; 22(12):2393-2398. PubMed ID: 33251659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Brueckmann M; Jamal W; Zeller C; Schnaidt S; Zannad F
    Circulation; 2021 Jan; 143(4):326-336. PubMed ID: 33081531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.